In the United States, a US-Israeli pharmaceutical company "Neuro-RX," and a Swiss drug development company "Relief Therapeutics" have received the go-ahead from the Food and Drug Administration (FDA) for phase two trials of a drug that could relieve some symptoms of COVID-19. The drug in question "Aviptadil" is a synthetic form of a neuropeptide hormone that works to enable communications between neurons in the human nervous system. The researchers are hoping that it will be able to take on the Acute Respiratory Distress Syndrome (ARDS), which is a respiratory system failure induced by rapid and severe lung inflammation, with shortness of breath.
top of page
bottom of page